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Available online 12 March 2016Aims: Retinoic acid has recently yielded promising results in the treatment of Cushing's disease, i.e., excess corti-
sol secretion due to a pituitary corticotropin (ACTH)-secreting adenoma. In addition to its effect on the tumoral
corticotrope cell, clinical results suggest an additional adrenal site of action. Aim of this study was to evaluate
whether retinoic acid modulates cortisol synthesis and secretion by human adrenals in vitro.
Main methods: Primary cultures from 10 human adrenals specimens were incubated with 10 nM, 100 nM and
1 μM retinoic acid with and without 10 nM ACTH for 24 h. Cortisol levels were measured by radioimmunoassay
and CYP11A1, STAR andMC2R gene expression analyzed by real-time PCR.
Key ﬁndings: Retinoic acid increased cortisol secretion (149.5 ± 33.01%, 151.3 ± 49.45% and 129.3 ± 8.32% con-
trol secretion for 10 nM, 100 nM and 1 μM respectively, p b 0.05) and potentiated STAR expression (1.51 ± 0.22,
1.56± 0.15 and 1.59 ± 0.14 fold change over baseline, for 10 nM, 100 nM and 1 μM respectively, p b 0.05). Con-
currently, retinoic acid markedly blunted constitutional and ACTH-induced MC2R expression (0.66 ± 0.11,
0.62 ± 0.08 and 0.53 ± 0.07 fold change over baseline, for 10 nM, 100 nM and 1 μM respectively, p b 0.05;
0.71± 0.10, 0.51± 0.07 and 0.51± 0.08 fold change over ACTH alone, for 10 nM, 100 nM and 1 μM respectively,
p b 0.05). No effect on CYP11A1 was observed.
Signiﬁcance: Retinoic acid stimulates cortisol synthesis and secretion in human adrenals and at the same time
markedly blunts ACTH receptor transcription. These results reveal a novel, adrenal effect of retinoic acid which
may contribute to its efﬁcacy in patients with Cushing's disease.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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STAR
MC2R1. Introduction
Retinoic acid is produced by the adrenal gland [1] and is involved in
adrenal embryonic development [2]. In vitro studies have also shown
that retinoic acidmodulates corticosteroid secretion and cell proliferation
in adrenal cancer cell lines [3,4].Most recently, retinoic acid has been pro-
posed for the treatment of Cushing's disease, i.e., excess cortisol secretion
due to a pituitary corticotropin (ACTH)-secreting tumor, a severe endo-
crine disorder lacking efﬁcacious medical therapy. In fact, retinoic acid
was shown to reduce ACTH secretion and inhibit cell proliferation in a
murine corticotrope tumor cell line [3,5,6]. Our pilot study in patients
with Cushing's disease [7] showed that administration of retinoic acid re-
duced and normalized excess cortisol secretion in a good proportion of
patients. During the course of this study we observed that retinoic acid
treatment resulted in a more potent decrease in cortisol than in ACTHmmunity Health, University of
Auxologico Italiano IRCCS, via
. This is an open access article underlevels.While this effectmay be due to the interplay between the two hor-
mones [8], it could also be due to a direct, adrenal action.
In Cushing's disease, the adrenal gland is either normal or hyperplas-
tic due to continued stimulation byACTH [9]. Thus, evidence collected in
adrenal cancer [3,4] may apply only in part. It appeared therefore of in-
terest to evaluate the effect of retinoic acid on the normal human adre-
nal cortex, in particular as regards cortisol secretion and ACTH-activated
steroidogenic gene expression.
2. Experimental
2.1. Adrenal cultures
Primary cultures from 10 human adrenal specimens were studied.
Normal human adrenal tissue was obtained from subjects submitted
to adrenalectomy for aldosteronism or non-functioning adenomas.
None of the patients presented clinical or hormonal features of
hypercortisolism. Adrenals cultures were established as per our usual
protocols [10,11]. In brief, adrenals were minced, digested in 0.1% colla-
genase, plated at approx. 300,000 cells/well, incubated in DMEM sup-
plemented with 10% fetal bovine serum and antibiotics for 3–5 days tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gery by the referring surgeon.
2.2. Treatments and assays
Cells were washed in DMEM containing 0.1% BSA for 1 h prior to in-
cubation with 10 nM, 100 nM and 1 μM 9-cis retinoic acid (Sigma Al-
drich, St. Louis, USA) alone and together with 10 nM ACTH for 24 h.
Pregnenolone (10 μM)was included in the testmedium in order to pro-
mote steroidogenesis [12]. Both pregnenolone and retinoic acid were
dissolved in 100% ethanol and diluted 1000-fold in DMEM; equal vol-
umes of ethanol were added to control wells. In each adrenal, treat-
ments were performed in triplicate. Cortisol was measured in medium
using Coat-A-Count radioimmunoassay (Siemens Healthcare Diagnos-
tics, Erlangen, Germany) and normalized to control or ACTH-
stimulated levels, respectively.
2.3. Quantitative real-time PCR
RNAwas extracted from plated cells using TRIzol reagent (Life Tech-
nologies, Carlsbad, USA) according to the manufacturer's instruction.
The amount and the quality of the RNA were checked on
nanophotometer (Implen GmbH, München, Germany) and 100 ng
RNA reverse-transcribed with Superscript Vilo cDNA Synthesis Kit
(Life Technologies, Carlsbad, USA). Quantitative Real-TimePCRwas per-
formed on a 7900 HT sequence Detection System (Applied Biosystems,
Foster City, USA), using the Platinum Quantitative PCR Supermix-UDG
with ROX (Life Technologies, Carlsbad, USA). The following genes
were evaluated: CYP11A1 (Taqman probe Hs00167984_m1), STAR
(Hs00264912_m1),MC2R (Hs00300820_s1) and normalized to RPLP0
(Hs99999902_m1). Expression data are analyzed as 2−ΔΔCt and
expressed as fold increase.
2.4. Statistical analyses
Data are expressed as mean ± standard error of the mean (S.E.M.)
and relative to control or ACTH-stimulated wells for each adrenal spec-
imen. Comparisons were performed using Wilcoxon's signed-rank test
and statistical signiﬁcance accepted at p b 0.05.Fig. 1.Mean cortisol changes in 10 human adrenal tissue primary cultures after 24 h incubation
panel shows ACTH-stimulated concentrations (ACTH stimulated wells = 100%). White bar: c
100 nM or 1 μM retinoic acid alone (left panel) or with 10 nM ACTH (right panel). * denotes p3. Results
Retinoic acid increased spontaneous cortisol secretion by human ad-
renals at all concentrations tested: 10 nM: 149.5 ± 33.01%, 100 nM:
151.3 ± 49.45% and 1 μM: 129.3 ± 8.32% unstimulated secretion (all
p b 0.05 vs control; Fig. 1, left panel).
As regards expression of steroidogenic genes, retinoic acid induced a
substantial increase in steroidogenic acute regulatory protein (STAR)
gene expression (10 nM: 1.51 ± 0.22, 100 nM: 1.56 ± 0.15 and 1 μM:
1.59 ± 0.14 fold change over control, all p b 0.05 vs control; Fig. 2,
right panel) and reduced expression of theACTH receptor,melanocortin
type receptor (MC2R; 10 nM: 0.66 ± 0.11, 100 nM: 0.62 ± 0.08 and
1 μM: 0.53 ± 0.07 fold change over control, all p b 0.05 vs control; Fig.
2, left panel) compared to unchallenged wells. No signiﬁcant changes
in CYP11A1, the gene coding for cytochrome P450 cholesterol side-
chain cleavage, the ﬁrst step in adrenal steroidogenesis, were observed
during treatment with retinoic acid (10 nM: 1.11 ± 0.11, 100 nM:
1.02 ± 0.05 and 1 μM: 1.03 ± 0.05 fold change over control, all N.S.)
Incubation with 10 nM ACTH evoked the expected increase in corti-
sol secretion (208.9 ± 63.71% constitutive secretion, p b 0.01) and
CYP11A1 (2.11 ± 0.28 fold change over control wells, p b 0.05), STAR
(3.73 ± 1.08 fold change over control wells, p b 0.05) andMCR2 gene
expression (11.9 ± 3.21 fold change over control wells, p b 0.01). Co-
incubation with retinoic acid induced a noticeable though non-
signiﬁcant increase in ACTH-stimulated cortisol secretion (10 nM:
139.8 ± 21.69%, 100 nM: 147.4 ± 25.48% and 1 μM: 131.7 ± 24.48%
ACTH-stimulated secretion, N.S.; Fig. 1, right panel). Of note, the in-
crease induced by retinoic acid duringACTH co-incubation did not differ
from the increase observed in absence of ACTH (paired comparison at
all three retinoic acid concentrations N.S.).
Retinoic acid co-incubation blunted the increase inMC2R expression
induced by ACTH (10 nM: 0.71± 0.10 fold change, 100 nM: 0.51± 0.08
fold change and 1 μM 0.52 ± 0.08 fold change over ACTH-stimulated
wells, all p b 0.05) whereas no signiﬁcant changes were observed as
regards CYP11A1 (10 nM: 1.19 ± 0.10 fold change, 100 nM 1.15 ±
0.13 fold change and 1 μM 1.07 ± 0.12 fold change over ACTH-
stimulated wells, all N.S.) and STAR (10 nM: 1.07 ± 0.19 fold change,
100 nM: 1.07 ± 0.22 fold change and 1 μM 1.37 ± 0.23 fold change
over ACTH-stimulated wells, all N.S., Supplemental Fig. 1). Changes in
MCR2 induced by retinoic acid with or without ACTH were comparable
for all three retinoic acid concentrations (all comparisons N.S.).with retinoic acid. Left panel shows spontaneous secretion (control wells = 100%), right
ontrol wells, graybar: incubation with 10 nM ACTH; black bars: incubation with 10 nM,
b 0.05 signiﬁcance vs control.
Fig. 2.MC2R and STAR expression in human adrenal primary cultures after 24 h incubationwith retinoic acid. Left panel showsmeanMC2R fold changes vs control wells, right panel shows
mean STAR fold changes vs control wells. White bar: control wells, black bars: incubation with 10 nM, 100 nM or 1 μM retinoic acid. * denotes p b 0.05 signiﬁcance vs control.
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The role of retinoic acid in adrenal embryonic development is well
known [2], indeed, retinoic acid-mediated transcription has been hy-
pothesized to play a role in adrenal hypoplasia due to DAX-1 (dosage-
sensitive sex reversal, adrenal hypoplasia critical region on chromo-
some X, gene 1) mutations [13,14]. In adrenal cancer cell lines, retinoic
acid has been shown to modulate corticosteroid secretion [3,4], thus
suggesting a role also later in life.
In parallel to this evidence, retinoic acid has recently been proposed
as a potential targeted therapy for Cushing's disease due to its action on
the tumoral corticotrope. Indeed, studies using a corticotrope tumor cell
line, AtT-20, reported that retinoic acid inhibits proopiomelanocortin
(POMC) synthesis and ACTH release via inhibition of Nur77/Nurr1 and
AP-1 (activator protein-1) [3,6]. Further, retinoic acid exerted an anti-
proliferative effect on AtT-20 cells which appeared to rely on induction
of bone morphogenetic protein-4 (BMP-4) [5,15], a member of the
transforming growth factor β (TGF-β) family with known actions on pi-
tuitary tumorigenesis [16] and of caspase 3 and 8 [6]. In this cell line,
retinoic acid also increased sensitivity to dopaminergic agents both as
regards cell viability and inhibition of POMC and ACTH [17]. An inhibi-
tory effect of retinoic acid was also observed in human tumoral
corticotrope primary cultures [3,17] which led to a pilot clinical trial in
patients with Cushing's disease [7]. Result of this study proved promis-
ing as did a study in dogs with endogenous hypercortisolism [18],
thereby conﬁrming the potential role of retinoic acid in treatment of
Cushing's disease.
These latter studies also suggested an additional action downstream
to the pituitary, i.e., on the adrenal, given that the effect of retinoic acid
on cortisol levelswasmoremarked than the change in plasmaACTH [7].
While this phenomenon is not uncommon for treatments which target
the pituitary in Cushing's disease [7,8,19], it could also be due to a direct
adrenal action. Given all the above, we decided to investigate the effect
of retinoic acid on cortisol secretion and on the synthesis of genes in-
volved in ACTH-stimulated steroid biosynthesis.
Our results show that retinoic acid stimulates cortisol release by nor-
mal human adrenal tissue and further, modulates STAR andMC2R, two
key factors in ACTH-driven steroidogenesis. Spontaneous cortisol re-
lease was increased on average by 30–50% during retinoic acid incuba-
tion whereas enhancement of the ACTH-stimulated cortisol responsewas less evident, possibly a consequence of its action on MC2R (see
below).
Retinoic acid increased the expression of STAR, the rate-limiting en-
zyme for adrenal cholesterol availability, thus triggering steroidogenesis
and rapid cortisol secretion [20]. Increased adrenal STAR synthesis and
protein expression has also been observed during liver X receptor
(LXR) agonist treatment inmice and appears to be due to LXR-RXR (ret-
inoid X receptor) heterodimer binding to the STAR promoter [21]. Sim-
ilar results have also been observed in mouse Leydig cells treated with
retinoic acid [22,23]. Conversely, no signiﬁcant changes in expression
of gene coding for theﬁrst step in adrenal steroidogenesis, i.e., P450 cho-
lesterol side-chain cleavage, were observed on retinoic acid, both with
and without ACTH co-incubation. CYP11A1 expression increased as ex-
pected during incubation with ACTH alone [20] but does not seem to
be a direct target of retinoic acid signaling in the normal adrenal gland.
Concurrently with increased cortisol release and STAR expression,
retinoic acid markedly reduced ACTH receptor expression. This was ev-
ident for baseline, constitutionalMC2R synthesis as well as during stim-
ulation with ACTH. In fact, the customary ACTH-induced increase in
MC2R [24,25] was nearly halved. This indicates that retinoic acid inter-
feres with mechanisms involved in adrenal ACTH receptor expression,
e.g., steroidogenic factor 1 (SF-1), cAMP, DAX-1 [26], or acts directly
upon the MC2R promoter. On the other hand, long-term treatment of
mice with an LXR agonist was associated with increased adrenalMC2R
expression [27], possibly a corollary to the known activation of the
hypothalamo-pituitary-adrenal axis by retinoids in vivo [28,29].
Perhaps not surprisingly, our data is in contrastwith results obtained
in adrenal cancer cell lines [3,4]. Studies performed on mouse and
human adrenal cancer cell lines reported an inhibitory effect of retinoic
acid on spontaneous and forskolin-stimulated steroid secretion [3,4].
Reduced expression of several enzymes involved in steroid hormone
biosynthesis, e.g., CYP11A1, HSD3B2, STAR, had also been observed dur-
ing retinoic acid or LXR/RXR agonist treatment in adrenal cancer cell
lines [4,30]. On the other hand, retinoic acid signaling and production
is altered in adrenal cancer [31,32] and, further, tumoral adrenal tissue
lacks COUP-TF I/II (chicken ovalbumin upstreampromoter transcription
factor I/II), one of the nuclear receptors involved in retinoic acid signal-
ing [33], which, conversely, is expressed in normal adrenal cells [34,35].
In Cushing's disease, adrenals are either normal or hyperplastic [9] thus
effects observed in neoplastic adrenals are unlikely to apply. Given our
280 A. Sesta et al. / Life Sciences 151 (2016) 277–280results on normal adrenals, further experiments on hyperplastic adrenal
tissues from patients with Cushing's disease are certainly worth
performing.
5. Conclusions
Our ﬁndings indicate that retinoic acid exerts a stimulatory effect on
cortisol synthesis and release by the normal adrenal. Concurrently,
retinoic acidmarkedly reduces expression of the adrenal ACTH receptor.
These ﬁndings suggest that the effect of retinoic acid in Cushing's dis-
ease is the result of the interplay between its action at pituitary and at
adrenal level.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.lfs.2016.03.023.
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